

## DAFTAR PUSTAKA

1. Hall, J. E., & Guyton AC. Guyton and Hall Textbook of Medical Physiology. 13th ed. Guyton and Hall Textbook Of Medical Physiology. London, England: Saunders/Elsevier; 2011.
2. Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. *BMJ*. 2020;371:m4087.
3. Jemal A, Torre L, Street W, Bray F. The Cancer Atlas - ACS. 2019.
4. WHO - World Health Organization. GLOBOCAN - Colorectal Cancer Incidence in The World. *Glob Cancer Obs*. 2020;419:1-2.
5. Kemenkes RI. Riset Kesehatan Dasar (Riskesdas) (2018) [Internet]. Vol. 53, Badan Penelitian dan Pengembangan Kesehatan Kementerian RI. Jakarta; 2018. Available from: [https://kesmas.kemkes.go.id/assets/upload/dir\\_519d41d8cd98f00/files/Hasil-riskesdas-2018\\_1274.pdf](https://kesmas.kemkes.go.id/assets/upload/dir_519d41d8cd98f00/files/Hasil-riskesdas-2018_1274.pdf)
6. The Global Cancer Observatory. Cancer Incident in Indonesia. *Int Agency Res Cancer*. 2020;858(1-2):1-2.
7. Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. *Nat Rev Dis Prim*. 2015;1:15065.
8. Grady WM, Markowitz SD. The Molecular Pathogenesis of Colorectal Cancer and Its Potential Application to Colorectal Cancer Screening. *Dig Dis Sci*. 2015;60(3):762-72.
9. Kemenkes RI. Panduan Penatalaksanaan Kanker kolorektal. Kementeri Kesehat Republik Indones. 2016;76.
10. Keku TO, Dulal S, Deveaux A, Jovov B, Han X. The gastrointestinal microbiota and colorectal cancer. *Am J Physiol - Gastrointest Liver Physiol*. 2015;308(5):G351-63.
11. Callejas BE, Martínez-Saucedo D, Terrazas LI. Parasites as negative regulators of cancer. *Biosci Rep*. 2018;38(5).
12. Berhe B, Bugssa G, Bayisa S, Alemu M. Foodborne intestinal protozoan infection and associated factors among patients with watery diarrhea in Northern Ethiopia; A cross-sectional study. *J Heal Popul Nutr*. 2018;37(1):1-7.
13. Fletcher SM, Stark D, Harkness J, Ellis J. Enteric protozoa in the developed world: A public health perspective. *Clin Microbiol Rev*. 2012;25(3):420-

49.

14. Dagne N, Alelign A. Prevalence of Intestinal Protozoan Parasites and Associated Risk Factors among School Children in Merhabete District, Central Ethiopia. *J Parasitol Res.* 2021;2021.
15. Wahdini S, Putra VP, Sungkar S. The prevalence of intestinal protozoan infections among children in southwest sumba based on the type of water sources. *Infect Chemother.* 2021;53(3):519–27.
16. Esteghamati A, Khanaliha K, Bokharaei-Salim F, Sayyahfar S, Ghaderipour M. Prevalence of intestinal parasitic infection in cancer, organ transplant and primary immunodeficiency patients in Tehran, Iran. *Asian Pacific J Cancer Prev.* 2019;20(2):495–501.
17. Banihashemi SM, Soleymani E, Abdizadeh R, Motavalli Haghi M, Khalili B. Intestinal Protozoan Infections in Cancer Patients Undergoing Chemotherapy in Shahrekord the Central Southwest of Iran in 2018. *Int J Epidemiol Res.* 2020;7(4):144–51.
18. Toychiev A, Abdujapparov S, Imamov A, Navruzov B, Davis N, Badalova N, et al. Intestinal helminths and protozoan infections in patients with colorectal cancer: prevalence and possible association with cancer pathogenesis. *Parasitol Res [Internet].* 2018;117(12):3715–23. Available from: <https://pubmed.ncbi.nlm.nih.gov/30220046/>
19. Marzain M, Nofita E, Semiarty R. Identifikasi Protozoa Usus pada Pasien yang Sedang Menjalani Kemoterapi di RSUP Dr M Djamil, Padang. *J Kesehat Andalas.* 2018;7(3):364.
20. Taghipour A, Rayatdoost E, Bairami A, Bahadory S, Abdoli A. Are Blastocystis hominis and Cryptosporidium spp. playing a positive role in colorectal cancer risk? A systematic review and meta-analysis. *Infect Agent Cancer.* 2022;17(1).
21. Kumarasamy V, Atroosh WM, Anbazhagan D, Abdalla MMI, Azzani M. Association of Blastocystis hominis with colorectal cancer: A systematic review of in vitro and in vivo evidences. *World J Gastrointest Oncol.* 2022;14(3):734–45.
22. Sawant M, Baydoun M, Creusy C, Chabé M, Viscogliosi E, Certad G, et al. Cryptosporidium and colon cancer: Cause or consequence? *Microorganisms.* 2020;8(11):1–15.
23. Kumarasamy V, Anbazhagan D, Subramaniyan V, Vellasamy S. Blastocystis sp., Parasite Associated with Gastrointestinal Disorders: An Overview of its Pathogenesis, Immune Modulation and Therapeutic Strategies. *Curr Pharm Des.* 2018;24(27):3172–5.
24. Siqueira-Neto JL, Debnath A, McCall LI, Bernatchez JA, Ndao M, Reed

- SL, et al. Cysteine proteases in protozoan parasites. *PLoS Negl Trop Dis*. 2018;12(8).
25. Sulżyc-Bielicka V, Kołodziejczyk L, Jaczewska S, Bielicki D, Safranow K, Bielicki P, et al. Colorectal cancer and *Cryptosporidium* spp. infection. *PLoS One*. 2018;13(4):1–12.
  26. American Cancer Society. What Is Cancer? [Internet]. [www.cancer.org](http://www.cancer.org). 2022 [accessed 2023 Feb]. Available from: <https://www.cancer.org/content/dam/CRC/PDF/Public/6041.00.pdf>
  27. Centers for Disease Control and Prevention (CDC). What Is Colorectal Cancer? | CDC [Internet]. Vol. 13, Centers for Disease Control and Prevention (CDC). 2021. p. 104–16. Available from: [https://www.cdc.gov/cancer/colorectal/basic\\_info/what-is-colorectal-cancer.htm](https://www.cdc.gov/cancer/colorectal/basic_info/what-is-colorectal-cancer.htm)
  28. American Society of Clinical Oncology (ASCO). Colorectal Cancer: Stages | Cancer.Net [Internet]. American Society of Clinical Oncology (ASCO). 2020. p. 1–5. Available from: <https://www.cancer.net/cancer-types/colorectal-cancer/stages>
  29. American Cancer Society K. American Cancer Society: Key statistics for colorectal cancer [Internet]. American Cancer Society. 2020. Available from: <http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-key-statistics>
  30. Asia S eastern S central, Asia S eastern S central, Ferlay J, Ervik M, Lam F, Colombet M, et al. Global Cancer Observatory: Cancer Today. Vol. 68, International Agency for Research on Cancer. 2020. p. 3–4.
  31. American Society Of Clinical Oncology. Colorectal Cancer: Risk Factors and Prevention [Internet]. [Cancer.Net](http://www.cancer.net). 2022. Available from: <https://www.cancer.net/cancer-types/colorectal-cancer/risk-factors-and-prevention>
  32. Mármol I, Sánchez-de-Diego C, Dieste AP, Cerrada E, Yoldi MJR. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. *Int J Mol Sci*. 2017;18(1).
  33. Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. *Cancers (Basel)*. 2021;13(9):104–16.
  34. Medina Pabón MA, Babiker HM. A Review Of Hereditary Colorectal Cancers. *StatPearls* [Internet]. 2019; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30855783>

35. Majumder S, Shivaji UN, Kasturi R, Sigamani A, Ghosh S, Iacucci M. Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives. *World J Gastrointest Oncol.* 2022;14(3):547–67.
36. Porter RJ, Arends MJ, Churchhouse AMD, Din S. Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines. *J Crohn's Colitis.* 2021;15(12):2131–41.
37. Amersi F, Agustin M, Ko CY. Colorectal cancer: epidemiology, risk factors, and health services. *Clin Colon Rectal Surg.* 2005;18(3):133–40.
38. Shussman N, Wexner SD. Colorectal polyps and polyposis syndromes. *Gastroenterol Rep.* 2014;2(1):1–15.
39. Yao C, Nash GF, Hickish T. Management of colorectal cancer and diabetes. *J R Soc Med.* 2014;107(3):103–9.
40. Ma Y, Yang W, Song M, Smith-Warner SA, Yang J, Li Y, et al. Type 2 diabetes and risk of colorectal cancer in two large U.S. prospective cohorts. *Br J Cancer.* 2018;119(11):1436–42.
41. Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. *Gastroenterology.* 2015;148(6):1244-1260.e16.
42. Huang YM, Wei PL, Ho CH, Yeh CC. Cigarette Smoking Associated with Colorectal Cancer Survival: A Nationwide, Population-Based Cohort Study. *J Clin Med.* 2022;11(4).
43. Rossi M, Anwar MJ, Usman A, Keshavarzian A, Bishehsari F. Colorectal cancer and alcohol consumption—populations to molecules. *Cancers (Basel).* 2018;10(2).
44. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell.* 2011;144(5):646–74.
45. Grady WM, Carethers JM. Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis. *Gastroenterology.* 2008;135(4):1079–99.
46. Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. *World J Gastroenterol.* 2008;14(25):3937–47.
47. Holtedahl K, Borgquist L, Donker GA, Buntinx F, Weller D, Campbell C, et al. Symptoms and signs of colorectal cancer, with differences between proximal and distal colon cancer: a prospective cohort study of diagnostic accuracy in primary care. *BMC Fam Pract.* 2021;22(1).
48. Shi Y, Wang M, Zhang J, Xiang Z, Li C, Zhang J, et al. Tailoring the clinical management of colorectal cancer by 18F-FDG PET/CT. *Front Oncol.* 2022;12.

49. Duan, Baojan; Zhao, Yaning; Bai Jun; Wang Jianhua; Luo, Xiaohui; Zhang, Rong; Pu Yansong; Kou, Mingqing; Lei, Jianyuan; Yang S. Colorectal cancer: An overview. *Pharm J*. 2022;
50. (CDC) C for DC and P. Colorectal Cancer Statistics. *Colorectal Cancer*. 2023. p. 4–7.
51. Soedarto, Inge Sutanto, Is Surahia Ismid, Pudji K SS. *Buku Ajar Parasitologi Kedokteran*. 4th ed. Vol. 41, *Handbook of Medical Parasitology*. Jakarta: FK UI; 2011. 384–386 p.
52. Fleming R, Cooper CJ, Ramirez-Vega R, Huerta-Alardin A, Boman D, Zuckerman MJ. Clinical manifestations and endoscopic findings of amebic colitis in a United States-Mexico border city: A case series. *BMC Res Notes*. 2015;8(1).
53. Centers for Disease Control and Prevention (CDC). Amebiasis [Internet]. 2019. Available from: <https://www.cdc.gov/dpdx/amebiasis/index.html>
54. Centers for Disease Control and Prevention (CDC). Giardiasis [Internet]. 2017. Available from: <https://www.cdc.gov/dpdx/giardiasis/index.html>
55. Dunn N J AL. Giardiasis [Internet]. Available from: [www.ncbi.nlm.nih.gov/books/NBK513239/](http://www.ncbi.nlm.nih.gov/books/NBK513239/)
56. Centers for Disease Control and Prevention (CDC). Blastocystis sp. Centers Dis Control Prev [Internet]. 2019; Available from: <https://www.cdc.gov/dpdx/blastocystis/index.html>
57. Wawrzyniak I, Poirier P, Texier C, Delbac F, Viscogliosi E, Dionigia M, et al. Blastocystis, an unrecognized parasite: An overview of pathogenesis and diagnosis. *Ther Adv Infect Dis*. 2013;1(5):167–78.
58. Osorio-Pulgarin MI, Higuera A, Beltran-álzate JC, Sánchez-Jiménez M, Ramírez JD. Epidemiological and molecular characterization of blastocystis infection in children attending daycare centers in medellín, Colombia. *Biology (Basel)*. 2021;10(7).
59. Padukone S, Mandal J, Rajkumari N, Bhat B, Swaminathan R, Parija S. Detection of Blastocystis in clinical stool specimens using three different methods and morphological examination in Jones' medium. *Trop Parasitol*. 2018;8(1):33–40.
60. Mossallam SF, El- Mansoury SAT, Tolba MM, Kohla AA, Khedr SI. In vitro susceptibility of human Blastocystis subtypes to simeprevir. *Saudi J Biol Sci*. 2021;28(4):2491–501.
61. Schuster FL, Ramirez-Avila L. Current world status of *Balantidium coli*. *Clin Microbiol Rev*. 2008;21(4):626–38.

62. (CDC) C for DC and P. Balantidiasis [Internet]. 2019. Available from: <https://www.cdc.gov/dpdx/balantidiasis/index.html>
63. Thakur N, Suresh R, Chethan GE, Mahendran K. Balantidiasis in an Asiatic elephant and its therapeutic management. *J Parasit Dis.* 2019;43(2):186–9.
64. Gerace E, Presti VDM Lo, Biondo C. Cryptosporidium infection: Epidemiology, pathogenesis, and differential diagnosis. *Eur J Microbiol Immunol.* 2019;9(4):119–23.
65. Centers for Disease Control and Prevention (CDC). Cryptosporidiosis [Internet]. Available from: <https://www.cdc.gov/dpdx/cryptosporidiosis/index.html>
66. Almeria S, Cinar HN, Dubey JP. Cyclospora cayetanensis and cyclosporiasis: An update. *Microorganisms.* 2019;7(9).
67. Centers for Disease Control and Prevention (CDC). cyclosporiasis [Internet]. 2019. Available from: <https://www.cdc.gov/dpdx/cyclosporiasis/index.html>
68. Cacciò SM. Molecular epidemiology of Dientamoeba fragilis. *Acta Trop.* 2018;184:73–7.
69. Centers for Disease Control and Prevention (CDC). Dientamoeba fragilis Infection [Internet]. 2019. Available from: <https://www.cdc.gov/dpdx/dientamoeba/index.html>
70. Garcia LS. Dientamoeba fragilis, one of the neglected intestinal protozoa. *J Clin Microbiol.* 2016;54(9):2243–50.
71. Nagata N, Marriott D, Harkness J, Ellis JT, Stark D. Current treatment options for Dientamoeba fragilis infections. *Int J Parasitol Drugs Drug Resist* [Internet]. 2012;2:204–15. Available from: [https://www.cdc.gov/parasites/dientamoeba/health\\_professionals/index.html](https://www.cdc.gov/parasites/dientamoeba/health_professionals/index.html)
72. Van Gestel RSFE, Kusters JG, Monkelbaan JF. A clinical guideline on Dientamoeba fragilis infections. *Parasitology.* 2019;146(9):1131–9.
73. Dubey JP, Almeria S. Cystoisospora belli infections in humans: The past 100 years. *Parasitology.* 2019;146(12):1490–527.
74. Centers for Disease Control and Prevention (CDC). Cystoisosporiasis [Internet]. Available from: <https://www.cdc.gov/dpdx/cystoisosporiasis/index.html>
75. Zhang N, Zhang H, Yu Y, Gong P, Li J, Li Z, et al. High prevalence of Pentatrichomonas hominis infection in gastrointestinal cancer patients.

Parasites and Vectors. 2019 Aug;12(1):423.

76. Centers for Disease Control and Prevention. Non-pathogenic flagellates [Internet]. DPDx. 2019. Available from: [https://www.cdc.gov/dpdx/nonpathogenic\\_flagellates/index.html](https://www.cdc.gov/dpdx/nonpathogenic_flagellates/index.html)
77. Dos Santos CS, McIntosh D, Berto BP, De Jesus VLT, Da Rocha CNC, Fernandes JI, et al. Diagnosis of Pentatrichomonas hominis from domestic cats in Southeastern Brazil. Rev Bras Med Vet. 2015 Nov;37:25–31.
78. Bastos BF, Brener B, de Figueiredo MA, Leles D, Mendes-De-almeida F. Pentatrichomonas hominis infection in two domestic cats with chronic diarrhea. J Feline Med Surg Open Reports. 2018;4(1):1–4.
79. Abdo SM, Ghallab MMI, Elhawary NM, Elhadad H. Pentatrichomonas hominis and other intestinal parasites in school-aged children: coproscopic survey. J Parasit Dis. 2022;
80. Mahittikorn A, Udonsom R, Koompapong K, Chiabchalard R, Sutthikornchai C, Sreepian PM, et al. Molecular identification of Pentatrichomonas hominis in animals in central and western Thailand. BMC Vet Res. 2021;17(1).
81. Compaoré C, Lekpa FK, Nebie L, Niamba P, Niakara A. Pentatrichomonas hominis infection in rheumatoid arthritis treated with adalimumab. Rheumatol (United Kingdom). 2013;52(8):1534–5.
82. Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome. 2015;3(1).
83. Fan X, Jin Y, Chen G, Ma X, Zhang L. Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer. Digestion. 2021;102(4):508–15.
84. Saus E, Iraola-Guzmán S, Willis JR, Brunet-Vega A, Gabaldón T. Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential. Mol Aspects Med. 2019;69:93–106.
85. Kim J, Lee HK. Potential Role of the Gut Microbiome In Colorectal Cancer Progression. Front Immunol. 2022;12.
86. Sataloff RT, Bush ML, Chandra R, Chepeha D, Rotenberg B, Fisher EW, et al. Systematic and other reviews: criteria and complexities. J Otolaryngol - Head Neck Surg. 2021;50(1).
87. Tawfik GM, Dila KAS, Mohamed MYF, Tam DNH, Kien ND, Ahmed AM, et al. A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health. 2019;47(1).
88. Abdel Hamed EF, Mostafa NE, Farag SM, Ibrahim MN, Ibrahim BH, Rashed HE, et al. Human protozoa infection and dysplasia in ulcerative

- colitis: a neglected aspect in a prominent disease. *Parasitol Res.* 2023 Nov;122(11):2709–18.
89. Juckett DA, Aylsworth CF, Quensen JM. Intestinal protozoa are hypothesized to stimulate immunosurveillance against colon cancer. *Med Hypotheses.* 2008;71(1):104–10.
  90. Munn Z, Stern C, Aromataris E, Lockwood C, Jordan Z. What kind of systematic review should i conduct? A proposed typology and guidance for systematic reviewers in the medical and health sciences. *BMC Med Res Methodol.* 2018;18(1).
  91. Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: An introduction to the JBI critical appraisal tool. *JBI Database Syst Rev Implement Reports.* 2019 Oct;18(10):2127–33.
  92. Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: Methodological development, conduct and reporting of an umbrella review approach. *Int J Evid Based Healthc.* 2015;13(3):132–40.
  93. AW H. Harzing's Publish or Perish [Internet]. 2007. Available from: <https://harzing.com/resources/publish-or-perish>
  94. Ltd M. Mendeley Desktop [Internet]. Glyph & Cog. 2008. Available from: <https://www.mendeley.com>
  95. Abd El-Latif NF, Kandil NS, Shamseya M, Elwany YN, Ibrahim HS. Role of *Cryptosporidium* spp in Development of Colorectal Cancer. *Asian Pac J Cancer Prev.* 2023 Feb;24(2):667–74.
  96. Labania L, Zoughbor S, Ajab S, Olanda M, Shantour SNM, Al Rasbi Z. The associated risk of Blastocystis infection in cancer: A case control study. *Front Oncol.* 2023;13:1115835.
  97. Ali SH, Ismail MAM, El-Badry AA, Abu-Sarea EY, Dewidar AM, Hamdy DA. An Association Between Blastocystis Subtypes and Colorectal Cancer Patients: A Significant Different Profile from Non-cancer Individuals. *Acta Parasitol.* 2022 Jun;67(2):752–63.
  98. Ghanadi K, Khalaf AK, Jafrasteh A, Anbari K, Mahmoudvand H. High prevalence of *Cryptosporidium* infection in Iranian patients suffering from colorectal cancer. *Parasite Epidemiol Control.* 2022 Nov;19:e00271.
  99. Haghghi L, Razmjou E, Rafiei-Sefiddashti R, Meamar AR, Akhlaghi L. *Entamoeba histolytica* and Probable Effect on Production Microsatellite Instability in Colorectal Cancer. *Curr Microbiol.* 2022 Feb;79(4):111.
  100. Öner TÖ, Karabey M, Can H, Döşkaya AD, ... Molecular investigation of



Blastocystis sp. and its subtypes in cancer patients under chemotherapy in Aegean region, Turkey. *Acta Trop* [Internet]. 2022; Available from: <https://www.sciencedirect.com/science/article/pii/S0001706X22002698>

101. Zhang H, Yu Y, Li J, Gong P, Wang X, Li X, et al. Changes of gut microbiota in colorectal cancer patients with *Pentatrichomonas hominis* infection. *Front Cell Infect Microbiol*. 2022;12.
102. Al-halaly ASS, Kadhumand HW, ... Detection of Virulence Genes for the *Entamoeba histolytic* Parasite in People with Colorectal Cancer. *Med Leg Updat* [Internet]. 2021; Available from: <https://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=0971720X&AN=152719744&h=oCrTaEsPbYgRcFShWO9K8vNZXy0NuBpuRGd3YTGCalv63CIAM84%2BgP216E7yZMloNsDzMEN9FZMnRDfndeiGGw%3D%3D&crl=c>
103. Hawash YA, Ismail KA, Saber T, Eed EM, Khalifa AS, Alsharif KF, et al. Predominance of Infection With *Blastocystis hominis* in Patients With Colorectal Cancer and Its Association With High Mucin Content, Infiltration of Inflammatory Cells and Elevated Serum Tumor Necrosis Factor  $\alpha$ . *Infect Dis Clin Pract* [Internet]. 2021;29(1). Available from: [https://journals.lww.com/infectdis/fulltext/2021/01000/predominance\\_of\\_infection\\_with\\_blastocystis.7.aspx](https://journals.lww.com/infectdis/fulltext/2021/01000/predominance_of_infection_with_blastocystis.7.aspx)
104. Mahmoudvand H, Sepahvand A, Badparva E, Khatami M, Niazi M, Moayyedkazemi A. Possible association and risk factors of blastocystis infection and colorectal cancers in western iran. *Arch Clin Infect Dis*. 2021;16(1).
105. Sawant M, Benamrouz-Vanneste S, Mouray A, Bouquet P, Gantois N, Creusy C, et al. Persistent *cryptosporidium parvum* infection leads to the development of the tumor microenvironment in an experimental mouse model: Results of a microarray approach [Internet]. Vol. 9, *Microorganisms*. mdpi.com; 2021. Available from: <https://www.mdpi.com/2076-2607/9/12/2569>
106. Ali Slwme. Serhan Al-halaly, Habeeb Waseel Kadhum Shubber. Study of Some Immunological Markers of People with Parasitic Infestation and their Relationship to Colorectal Cancer. *Med Leg Updat*. 2021;21(2):82–8.
107. Sulżyc-Bielicka V, Kołodziejczyk L, Adamska M, Skotarczak B, Jaczewska S, Safranow K, et al. Colorectal cancer and *Blastocystis sp.* infection. *Parasites and Vectors* [Internet]. 2021 Apr;14(1):200. Available from: <https://doi.org/10.1186/s13071-021-04681-x>
108. Nasir KA, Hama AA, Ali SI. Prevalence of *Cryptosporidiosis* Among Cancer Patients in Sulaimani Province [Internet]. Vol. 24, *Cryptosporidium Infection: Epidemiology, Pathogenesis, and Differential Diagnosis*. researchgate.net; 2020. p. 1906–15. Available from:

[https://www.researchgate.net/profile/Drabdullah-Hama/publication/341766804\\_Prevalence\\_of\\_Cryptosporidiosis\\_among\\_Cancer\\_Patients\\_in\\_Sulaimani\\_ProvinceIraq/links/5ed2ad1b92851c9c5e678ffd/Prevalence-of-Cryptosporidiosis-among-Cancer-Patients-in-Sulaimani-Pr](https://www.researchgate.net/profile/Drabdullah-Hama/publication/341766804_Prevalence_of_Cryptosporidiosis_among_Cancer_Patients_in_Sulaimani_ProvinceIraq/links/5ed2ad1b92851c9c5e678ffd/Prevalence-of-Cryptosporidiosis-among-Cancer-Patients-in-Sulaimani-Pr)

109. Zhang N, Yu X, Zhang H, Cui L, Li X, Zhang X, et al. Prevalence and genotyping of cryptosporidium parvum in gastrointestinal cancer patients. *J Cancer*. 2020;11(11):3334–9.
110. Kopacz Z, Kvá M, Karpinski P, Hendrich AB, Sasiadek MM, Leszczynski P, et al. The first evidence of cryptosporidium meleagridis Infection in a Colon Adenocarcinoma from an Immunocompetent Patient. *Front Cell Infect Microbiol*. 2019;9(MAR):35.
111. Mahmoudvand H, Sepahvand A, Khatami M, Moayyedkazemi A. Prevalence and associated risk factors of *Cystoisospora belli* and *Cyclospora cayentanensis* infection among Iranian patients with colorectal cancer. *J Parasit Dis*. 2019 Sep;43(3):402–5.
112. Majeed GH, Mohammed NS, Muhsen SS. The synergistic effect of blastocystis hominis and h. Pylori in iraqi colorectal cancer patients. *J Pharm Sci Res* [Internet]. 2019;11(2):523–6. Available from: <https://www.embase.com/search/results?subaction=viewrecord&id=L2001628696&from=export>
113. Essid R, Menotti J, Hanen C, Aoun K, Bouratbine A. Genetic diversity of *Cryptosporidium* isolates from human populations in an urban area of Northern Tunisia. *Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis*. 2018 Mar;58:237–42.
114. Sulżyc-Bielicka V, Kołodziejczyk L, Jaczevska S, Bielicki D, Safranow K, Bielicki P, et al. Colorectal cancer and *Cryptosporidium* spp. infection. *PLoS One*. 2018;13(4):e0195834.
115. Al-dabbagh LKA, Al-mukhtar PAM. Infections with *Blastocystis hominis* in patients with colorectal cancer in Mosul city , Iraq. 2017;6(9):7–10.
116. Kumarasamy V, Kuppusamy UR, Jayalakshmi P, Samudi C, Ragavan ND, Kumar S. Exacerbation of colon carcinogenesis by *Blastocystis* sp. *PLoS One*. 2017;12(8):e0183097.
117. Mohamed AM, Ahmed MA, Ahmed SA, Al-Semany SA, Alghamdi SS, Zagloul DA. Predominance and association risk of *Blastocystis hominis* subtype i in colorectal cancer: A case control study. *Infect Agent Cancer*. 2017;12(1):21.
118. Osman M, Benamrouz S, Guyot K, Baydoun M, Frealle E, Chabe M, et al. High association of cryptosporidium spp. infection with colon

adenocarcinoma in Lebanese patients. *PLoS One*. 2017;12(12).

119. Yersal O, Malatyali E, Ertabaklar H, Oktay E, Barutca S, Ertug S. Blastocystis subtypes in cancer patients: Analysis of possible risk factors and clinical characteristics. *Parasitol Int* [Internet]. 2016;65(6):792–6. Available from: <https://www.sciencedirect.com/science/article/pii/S1383576916300149>
120. Benamrouz S, Conseil V, Chabé M, Praet M, Audebert C, Blervaque R, et al. *Cryptosporidium parvum*-induced ileo-caecal adenocarcinoma and Wnt signaling in a mouse model. *DMM Dis Model Mech*. 2014;7(6):693–700.
121. Chandramathi S, Suresh K, Sivanandam S, Kuppusamy UR. Stress exacerbates infectivity and pathogenicity of *Blastocystis hominis*: In vitro and in vivo evidences. *PLoS One* [Internet]. 2014 May;9(5). Available from: <https://www.proquest.com/scholarly-journals/stress-exacerbates-infectivity-pathogenicity/docview/1520572136/se-2?accountid=38628>
122. Kumarasamy V, Roslani AC, Rani KU, Kumar Govind S. Advantage of using colonic washouts for *Blastocystis* detection in colorectal cancer patients. *Parasites and Vectors*. 2014 Apr;7(1):162.
123. El-Latif NFA, Kandil NS, Shamsya M, Elwany YN, Ibrahim HS. Role of *Cryptosporidium* spp in Development of Colorectal Cancer. *Asian Pacific J Cancer Prev*. 2023 Feb;24(2):667–74.
124. Arbaniah N. Deteksi Parasit Intestinal pada Pasien Kanker Kolorektal di RSUP Dr. M. Djamil Padang Tahun 2023. *Andalas University*; 2024.
125. Rudzińska M, Sikorska K. Epidemiology of *Blastocystis* Infection: A Review of Data from Poland in Relation to Other Reports. *Pathogens*. 2023;12(8).
126. Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, et al. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. *Oncoimmunology*. 2015 Apr;4(4):e1008814.
127. Kagawa K, Fujino H, Miki H, Sogabe K, Takahashi M, Maruhashi T, et al. *Cryptosporidiosis* in a transplant recipient with severe intractable diarrhea: Detection of *Cryptosporidium* oocysts by intestinal biopsies. *Transpl Infect Dis*. 2018;20(2).
128. Nasir KA, Hama AA, Ali SI. Prevalence of *Cryptosporidiosis* among cancer patients in Sulaimani province/Iraq [Internet]. *Int J Psychosoc Rehabil*. researchgate.net; 2020. Available from: [https://www.researchgate.net/profile/Drabdullah-Hama/publication/341766804\\_Prevalence\\_of\\_Cryptosporidiosis\\_among\\_Cancer\\_Patients\\_in\\_Sulaimani\\_ProvinceIraq/links/5ed2ad1b92851c9c5e678ffd/Prevalence-of-Cryptosporidiosis-among-Cancer-Patients-in-Sulaimani-](https://www.researchgate.net/profile/Drabdullah-Hama/publication/341766804_Prevalence_of_Cryptosporidiosis_among_Cancer_Patients_in_Sulaimani_ProvinceIraq/links/5ed2ad1b92851c9c5e678ffd/Prevalence-of-Cryptosporidiosis-among-Cancer-Patients-in-Sulaimani-)

Pr

129. Sulżyc-Bielicka V, Kołodziejczyk L, Adamska M, Skotarczak B, Jaczewska S, Safranow K, et al. Colorectal cancer and Blastocystis sp. infection. *Parasites and Vectors* [Internet]. 2021;14(1):1–9. Available from: <https://doi.org/10.1186/s13071-021-04681-x>
130. Jeske S, Bianchi TF, Moura MQ, Baccega B, Pinto NB, Berne MEA, et al. Intestinal parasites in cancer patients in the south of Brazil. *Brazilian J Biol.* 2018;78(3):574–8.
131. Chandramathi S, Suresh K, Sivanandam S, ... Stress Exacerbates Infectivity and Pathogenicity of Blastocystis hominis: In Vitro and In Vivo Evidences [Internet]. *PloS one. journals.plos.org*; 2014. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0094567>
132. Soleimani Jevinani S, Mohammad Rahimi H, Asri N, Rostami-Nejad M, Ahmadipour S, Mirjalali H. Molecular epidemiology and subtyping of Blastocystis sp. and its subtypes in celiac patients; a case control study. *Microb Pathog* [Internet]. 2023;179. Available from: <https://www.sciencedirect.com/science/article/pii/S0882401023001195>
133. Quintanilla I, López-Cerón M, Jimeno M, Cuatrecasas M, Zabalza M, Moreira L, et al. Rectal aberrant crypt foci in humans are not surrogate markers for colorectal cancer risk. *Clin Transl Gastroenterol.* 2019;10(6).
134. Kalantari N, Gorgani-Firouzjaee T, Ghaffari S, Bayani M, Ghaffari T, Chehrazi M. Association between Cryptosporidium infection and cancer: A systematic review and meta-analysis. *Parasitol Int.* 2020;74.
135. de Sablet T, Potiron L, Marquis M, Bussière FI, Lacroix-Lamandé S, Laurent F. Cryptosporidium parvum increases intestinal permeability through interaction with epithelial cells and IL-1 $\beta$  and TNF $\alpha$  released by inflammatory monocytes. *Cell Microbiol.* 2016;18(12):1871–80.
136. Li X, Li J, Zhang X, Yang Z, Yang J, Gong P. Prevalence of Pentatrichomonas hominis infections in six farmed wildlife species in Jilin, China. *Vet Parasitol.* 2017;244:160–3.
137. Ağagündüz D, Cocozza E, Cemali Ö, Bayazıt AD, Nani MF, Cerqua I, et al. Understanding the role of the gut microbiome in gastrointestinal cancer: A review. *Front Pharmacol.* 2023;14.
138. Zeinalian M, Hashemzadeh-Chaleshtori M, Salehi R, Emami M. Clinical Aspects of Microsatellite Instability Testing in Colorectal Cancer. *Adv Biomed Res.* 2018;7(1):28.
139. Öncü Öner T, Karabey M, Can H, Değirmenci Döşkaya A, Karakavuk M, Gül A, et al. Molecular investigation of Blastocystis sp. and its subtypes in cancer patients under chemotherapy in Aegean region, Turkey. *Acta Trop*

- [Internet]. 2022;233. Available from: <https://www.sciencedirect.com/science/article/pii/S0001706X22002698>
140. Nieto Clavijo C, Morales L, Márquez Ortiz RA, Romero Sánchez C, Ramos Casallas A, Escobar Pérez J, et al. Microbioma intestinal diferencial en pacientes con espondiloartritis asociada a colonización de Blastocystis. 2023; Available from: <https://repositorio.unbosque.edu.co/handle/20.500.12495/11325>
  141. CRUK. Bowel cancer incidence statistics [Internet]. Cancer Research UK. 2017. Available from: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/incidence#heading-Zero%25Ahttps://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/incidence%25>
  142. Maciel-Fiuza MF, Muller GC, Campos DMS, do Socorro Silva Costa P, Peruzzo J, Bonamigo RR, et al. Role of gut microbiota in infectious and inflammatory diseases. *Front Microbiol.* 2023;14.
  143. Tankovic J, Burghoffer B, Petit JC. R2084 Frequent detection by real-time PCR of bacteria from the Helicobacter and Campylobacter genera in stool samples from inflammatory bowel disease patients. *Clin ...* [Internet]. Available from: [https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X\(14\)64714-5/abstract](https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(14)64714-5/abstract)
  144. Abedi J, Saatloo MV, Nejati V, Hobbenaghi R, Tukmechi A, Nami Y, et al. Selenium-Enriched *Saccharomyces cerevisiae* Reduces the Progression of Colorectal Cancer. *Biol Trace Elem Res.* 2018;185(2):424–32.
  145. Sambrani R, Abdolalizadeh J, Kohan L, Jafari B. *Saccharomyces cerevisiae* inhibits growth and metastasis and stimulates apoptosis in HT-29 colorectal cancer cell line. *Comp Clin Path.* 2019;28(4):985–95.
  146. Grillo F, Campora M, Carlin L, Cornara L, Parente P, Vanoli A, et al. “Stranger things” in the gut: uncommon items in gastrointestinal specimens. *Virchows Arch.* 2022;480(2):231–45.
  147. Bouzid M, Kintz E, Hunter PR. Risk factors for *Cryptosporidium* infection in low and middle income countries: A systematic review and meta-analysis. *PLoS Negl Trop Dis.* 2018;12(6).
  148. Sarkari B, Hosseini G, Motazedian MH, Fararouei M, Moshfe A. Prevalence and risk factors of intestinal protozoan infections: A population-based study in rural areas of Boyer-Ahmad district, Southwestern Iran. *BMC Infect Dis.* 2016;16(1).
  149. Matovelle C, Tejedor MT, Monteagudo LV, Beltrán A, Quílez J.

Prevalence and Associated Factors of Blastocystis sp. Infection in Patients with Gastrointestinal Symptoms in Spain: A Case-Control Study. *Trop Med Infect Dis* [Internet]. 2022;7(9). Available from: <https://www.mdpi.com/2414-6366/7/9/226>

150. Hamdy DA, Abd El Wahab WM, Senosy SA, Mabrouk AG. Blastocystis spp. and Giardia intestinalis co-infection profile in children suffering from acute diarrhea. *J Parasit Dis* [Internet]. 2020;44(1):88–98. Available from: <https://link.springer.com/article/10.1007/s12639-019-01165-9>
151. Ajjampur SSR, Tan KSW. Pathogenic mechanisms in Blastocystis spp. — Interpreting results from in vitro and in vivo studies. *Parasitol Int*. 2016;65(6):772–9.

